These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 15361504)

  • 41. Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response.
    Imai Y; Kasahara A; Tanaka H; Okanoue T; Hiramatsu N; Tsubouchi H; Yoshioka K; Kawata S; Tanaka E; Hino K; Hayashi K; Tamura S; Itoh Y; Sasaki Y; Kiyosawa K; Kakumu S; Okita K; Hayashi N
    J Gastroenterol; 2004 Nov; 39(11):1069-77. PubMed ID: 15580400
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients.
    Nishikawa H; Iguchi E; Koshikawa Y; Ako S; Inuzuka T; Takeda H; Nakajima J; Matsuda F; Sakamoto A; Henmi S; Hatamaru K; Ishikawa T; Saito S; Kita R; Kimura T; Osaki Y
    BMC Res Notes; 2012 Mar; 5():135. PubMed ID: 22405406
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].
    Pár A; Tornai I; Szalay F
    Orv Hetil; 2007 May; 148(18):819-26. PubMed ID: 17468063
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characteristics and prognosis of hepatocellular carcinoma detected in sustained responders to interferon therapy for chronic hepatitis C.
    Toyoda H; Kumada T; Hayashi K; Honda T; Morita K; Nishimura D; Imada K; Imoto M; Horiguchi Y; Nakano H; Nakano I; Fukuda Y;
    Cancer Detect Prev; 2003; 27(6):498-502. PubMed ID: 14642559
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon.
    Veldt BJ; Hansen BE; Ikeda K; Verhey E; Suzuki H; Schalm SW
    Scand J Gastroenterol; 2006 Sep; 41(9):1087-94. PubMed ID: 16938723
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan.
    Huang JF; Yu ML; Lee CM; Dai CY; Hou NJ; Hsieh MY; Wang JH; Lu SN; Sheen IS; Lin SM; Chuang WL; Liaw YF
    Aliment Pharmacol Ther; 2007 May; 25(9):1029-37. PubMed ID: 17439503
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C.
    Teuber G; Berg T; Hoffmann RM; Leifeld L; Lafrenz M; Spengler U; Pape GR; Hopf U; Zeuzem S
    Digestion; 2000; 61(2):90-7. PubMed ID: 10705172
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C.
    Bizollon T; Pradat P; Mabrut JY; Chevallier M; Adham M; Radenne S; Souquet JC; Ducerf C; Baulieux J; Zoulim F; Trepo C
    Am J Transplant; 2005 Aug; 5(8):1909-13. PubMed ID: 15996238
    [TBL] [Abstract][Full Text] [Related]  

  • 49. α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response.
    Tachi Y; Hirai T; Ishizu Y; Honda T; Kuzuya T; Hayashi K; Ishigami M; Goto H
    J Gastroenterol Hepatol; 2016 May; 31(5):1001-8. PubMed ID: 27123974
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Daily interferon induction regimen using different manufactured interferons (alpha-2A or alpha-2B) in combination with ribavirin for treatment of chronic hepatitis C: a prospective randomized study.
    Braga EL; Lyra AC; Nascimento L; Netto E; Kalabrik L; Lyra LG
    Arq Gastroenterol; 2006; 43(4):275-9. PubMed ID: 17406754
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interferon retreatment reduces or delays the incidence of hepatocellular carcinoma in patients with chronic hepatitis C.
    Hino K; Kitase A; Satoh Y; Fujiwara D; Yamaguchi Y; Korenaga M; Shingai Y; Konishi T; Yamashita S; Uchida K; Mori K; Hanada H; Kodama T; Nukui K; Okita K
    J Viral Hepat; 2002 Sep; 9(5):370-6. PubMed ID: 12225332
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Favorable Prognosis in Patients with Sustained Virological Response to Antiviral Therapy, Including Interferon, for Chronic Hepatitis C Before Hepatic Resection for Hepatocellular Carcinoma.
    Shirabe K; Sugimachi K; Harada N; Kayashima H; Maeda T; Tsujita E; Minagawa R; Kajiyama K; Yoshiya S; Maehara Y
    Anticancer Res; 2015 Dec; 35(12):6963-9. PubMed ID: 26637923
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Do steatosis and steatohepatitis impact on sustained virological response (SVR) rates in patients receiving pegylated interferon and ribavirin for chronic hepatitis C infection?
    Cross TJ; Quaglia A; Nolan J; Hughes S; Harrison PM
    J Med Virol; 2010 May; 82(6):958-64. PubMed ID: 20419809
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
    Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
    Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients.
    Giannini EG; Basso M; Savarino V; Picciotto A
    Aliment Pharmacol Ther; 2010 Feb; 31(4):502-8. PubMed ID: 19925499
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response.
    Kim GA; Han S; Kim HD; An J; Lim YS
    J Viral Hepat; 2017 Nov; 24(11):990-997. PubMed ID: 28499070
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Monitoring virological responses to interferon-ribavirin and interferon monotherapy of chronic hepatitis C re-treated due to relapse or non-response.
    Westin J; Lindh M; Nenonen N; Lagging LM; Norkrans G; Wejstål R
    Scand J Infect Dis; 2001; 33(2):110-5. PubMed ID: 11233844
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C.
    Hanrotel C; Toupance O; Lavaud S; Thiefin G; Brodard V; Ingrand D; Diebold MD; Wynckel A; Chanard J
    Nephron; 2001 Jun; 88(2):120-6. PubMed ID: 11399913
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C.
    Yoshida H; Tateishi R; Arakawa Y; Sata M; Fujiyama S; Nishiguchi S; Ishibashi H; Yamada G; Yokosuka O; Shiratori Y; Omata M
    Gut; 2004 Mar; 53(3):425-30. PubMed ID: 14960528
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of interferon-alpha induction therapy on genotype 2b/3a and low viral load hepatitis C virus infection. A randomized multicentre study.
    Bjøro K; Bell H; Myrvang B; Skaug K; Raknerud N; Sandvei P; Størseth S; Ritland S; Lund-Tønnesen S; Bucher A; Hellum KB
    Scand J Gastroenterol; 2002 Mar; 37(3):344-9. PubMed ID: 11916198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.